MedTrace Logo

Protective Effect of Phenytoin on Glaucoma

NCT00739154 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2008-08-21

No results posted yet for this study

Summary

since glaucoma is considered an optic neuropathy, new treatments for glaucoma are being continuously investigated, including neuroprotection.

Previous studies implied that phenytoin, a potent anti-convulsive drug, has a neuroprotective role, and Na+ channels blockage was suggested as a possible mechanism.

This study predicts that glaucoma patients taking Phenytoin will have a less advanced glaucoma as compared to patients not taking the drug. Glaucoma severity will be determined by visual acuity, visual fields, optic disc cupping and nerve fiber layer thickness

Conditions

  • Primary Open Angle Glaucoma
  • Secondary Open Angle Glaucoma
  • Narrow-Angle Glaucomas
  • Normal Tension Glaucoma

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Omer Y Bialer, MD · Rabin medical center, Petah Tikva, Israel

  • Dan Gaa'ton, MD · Rabin medical center, Petah-Tikva, Israel

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-11-30
Completion
2010-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00739154 on ClinicalTrials.gov